6533b82ffe1ef96bd1295184
RESEARCH PRODUCT
Caffeinated coffee consumption and risk of atrial fibrillation in two Spanish cohorts
Miguel-angel MuñozJordi Salas-salvadóLuis Serra-majemLuis Serra-majemJosep BasoraRamon EstruchRamon EstruchJosé LapetraAlfredo GeaAlfredo GeaP. BazalDolores CorellaDolores CorellaMontse FitóMiguel Ruiz-canelaMiguel Ruiz-canelaÁNgel M. Alonso-gómezCarlos Muñoz-bravoJavier RekondoAdela M NavarroMiquel FiolJosé V. SorlíJosé V. SorlíEmilio RosMiguel ÁNgel Martínez-gonzálezMiguel ÁNgel Martínez-gonzálezMiguel ÁNgel Martínez-gonzálezEstefanía ToledoEstefanía Toledosubject
AdultInverse AssociationMediterranean dietEpidemiology030204 cardiovascular system & hematologyCoffeeCohort Studies03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsMediterranean dietCaffeineEnvironmental healthAtrial FibrillationmedicineHumansProspective Studies030212 general & internal medicineAgedProportional Hazards ModelsConsumption (economics)business.industryAtrial fibrillationCaffeinated coffeemedicine.diseasechemistryCardiology and Cardiovascular MedicinebusinessCaffeinedescription
Aims: The association between caffeinated coffee consumption and atrial fibrillation remains unclear. Recent studies suggest an inverse association only between a moderate caffeinated coffee consumption and atrial fibrillation, but others have reported no association. The aim of our study was to prospectively assess the association between caffeinated coffee consumption and atrial fibrillation in two Spanish cohorts, one of adults from a general population and another of elderly participants at high cardiovascular risk. Methods and results: We included 18,983 and 6479 participants from the 'Seguimiento Universidad de Navarra' (SUN) and 'Prevención con Dieta Mediterránea' (PREDIMED) cohorts, respectively. Participants were classified according to their caffeinated coffee consumption in three groups: ≤3 cups/month, 1-7 cups/week, and >1 cup/day. We identified 97 atrial fibrillation cases after a median follow-up of 10.3 years (interquartile range 6.5-13.5), in the SUN cohort and 250 cases after 4.4 years median follow-up (interquartile range 2.8-5.8) in the PREDIMED study. No significant associations were observed in the SUN cohort although a J-shaped association was suggested. A significant inverse association between the intermediate category of caffeinated coffee consumption (1-7 cups/week) and atrial fibrillation was observed in PREDIMED participants with a multivariable-adjusted hazard ratio = 0.53 (95% confidence interval 0.36-0.79) when compared with participants who did not consume caffeinated coffee or did it only occasionally. No association was found for higher levels of caffeinated coffee consumption (>1 cup per day), hazard ratio = 0.79 (95% confidence interval 0.49-1.28). In the meta-analysis of both PREDIMED and SUN studies, the hazard ratio for intermediate consumption of caffeinated coffee was 0.60 (95% confidence interval 0.44-0.82) without evidence of heterogeneity. Similar findings were found for the association between caffeine intake and atrial fibrillation risk. Conclusion: Intermediate levels of caffeinated coffee consumption (1-7 cups/week) were associated with a reduction in atrial fibrillation risk in two prospective Mediterranean cohorts. The author(s) received no financial support for the research, authorship, and/or publication of this article and had full access to all of the data in this study. The SUN Project was supported by the Spanish Government-Instituto de Salud Carlos III, and the European Regional Development Fund (RD 06/0045, PI14/ 01798, PI14/01764, PI17/01795), the Navarra Regional Government, and the University of Navarra. An Advanced Research Grant from the European Research Council to Miguel A Martínez-González (agreement #340918-PREDIMED-Plus) is duly acknowledged. PREDIMED trial was supported by the official funding agency for biomedical research of the Spanish government (Instituto de Salud Carlos III) RTIC G03/140 (Coordinator: Dr Estruch) and RTIC RD 06/0045 (Coordinator: Dr Martínez-González). We also acknowledge grants from the National Institutes of Health, United States (1R01HL118264-01); Fondo de Investigación Sanitaria Fondo Europeo de Desarrollo Regional (PI04/0233, PI05/0976, PI07/0240, PI10/01407, PI10/02658, PI11/00049, PI11/02505 and AGL2010-22319-C03-03); Consejería de Salud de la Junta de Andalucía (PI0105/2007), and by the Generalitat Valenciana, Spain (ACOMP/2013/165 and ACOMP/2013/159).
year | journal | country | edition | language |
---|---|---|---|---|
2019-10-29 | European Journal of Preventive Cardiology |